Overview
Treatment-resistant depression (TRD) affects approximately 30% of patients with major depressive disorder. Two of the most significant advances for TRD are ketamine-based therapies -- targeting the glutamate system through NMDA receptor antagonism and downstream neuroplasticity -- and transcranial magnetic stimulation (TMS), which uses focused magnetic pulses to modulate brain regions involved in mood regulation. They differ profoundly in mechanism, administration, side effects, and treatment timeline.
Mechanism of Action
| Mechanism | Ketamine Therapy | TMS Therapy |
|---|---|---|
| Primary modality | Pharmacological | Electromagnetic |
| Target system | Glutamate / NMDA receptors | Cortical neural circuits |
| Primary brain target | Diffuse (prefrontal, hippocampal, limbic) | Left DLPFC (standard protocol) |
| Downstream effects | BDNF, mTOR, synaptogenesis | Cortical excitability, connectivity normalization |
| Systemic exposure | Yes (whole-body drug distribution) | No (focal brain stimulation) |
| Effect on neuroplasticity | Rapid, chemically mediated | Gradual, activity-dependent |
Ketamine blocks NMDA receptors, disinhibiting glutamate release and triggering the BDNF-TrkB-mTOR cascade that promotes rapid synaptogenesis within hours (Duman et al., 2016). TMS uses magnetic pulses to induce electrical currents in cortical tissue, typically applying high-frequency stimulation to the left dorsolateral prefrontal cortex (DLPFC) to increase cortical excitability and modulate deeper limbic structures (George et al., 2010). Because TMS involves no pharmacological agent, it eliminates systemic drug exposure but cannot match ketamine's rapid onset.
Treatment Protocols
| Protocol Element | Ketamine Therapy | TMS Therapy |
|---|---|---|
| Session duration | 40-60 min (IV infusion) | 19-37 min (standard); 3-10 min (theta burst) |
| Sessions for acute course | 6 infusions over 2-3 weeks | 30-36 sessions over 6-9 weeks |
| Session frequency | 2-3 times per week | 5 times per week (daily M-F) |
| Total treatment time | 2-3 weeks (acute) | 6-9 weeks (acute) |
| Maintenance protocol | Variable (weekly to monthly) | Variable (taper or as-needed) |
| Time commitment per week | 3-6 hours | 2.5-5 hours |
The standard IV ketamine protocol involves six infusions of 0.5 mg/kg over 2-3 weeks, with maintenance every 2-4 weeks. Standard rTMS involves 30-36 daily sessions over 6-9 weeks. The Stanford SAINT protocol compressed TMS to five consecutive days using theta-burst stimulation, with Cole et al. (2020) reporting 86% remission in American Journal of Psychiatry.
Clinical: The treatment timeline difference is one of the most important practical distinctions. A patient in acute crisis with severe TRD and suicidal ideation may benefit from ketamine's hours-to-days onset, whereas TMS requires weeks to produce its full effect. Conversely, a stable TRD patient seeking a non-pharmacological intervention with durable effects may prefer TMS despite its longer treatment course.
Efficacy Comparison
| Efficacy Metric | Ketamine Therapy | TMS Therapy |
|---|---|---|
| Acute response rate | 60-70% (within 24 hours) | 50-60% (after full course) |
| Remission rate | 30-40% (acute) | 30-35% (after full course) |
| Onset of response | Hours | 2-4 weeks |
| Duration of response | Days to weeks (single dose) | Months (after full course) |
| Effect on suicidal ideation | Rapid, well-documented | Minimal acute data |
| NNT (number needed to treat) | ~3-4 | ~4-5 |
| Evidence quality | 40+ RCTs | Multiple large RCTs, FDA data |
Kishimoto et al. (2016) found IV ketamine produced response in 60-70% of TRD patients within 24 hours (NNT approximately 3-4). For suicidal ideation, Wilkinson et al. (2018) demonstrated significant reductions within 24 hours -- unmatched by any other intervention.
O'Reardon et al. (2007) demonstrated that rTMS produced significantly greater remission than sham stimulation. The NeuroStar registry (Carpenter et al., 2012) reported real-world response of 58% and remission of 37%. A critical TMS advantage is durability: Dunner et al. (2014) reported 62.5% of responders maintained benefit at 12 months.
Side Effect Profiles
| Side Effect | Ketamine Therapy | TMS Therapy |
|---|---|---|
| Dissociation | Common (dose-dependent) | Not applicable |
| Headache | 15-25% | 25-40% (most common) |
| Scalp discomfort | Not applicable | 20-30% |
| Nausea | 15-30% | Rare (<5%) |
| Blood pressure changes | 20-35% elevation | Not significant |
| Dizziness | 20-30% | 5-10% |
| Sedation | Common | Not applicable |
| Seizure risk | Very rare | Very rare (<0.1%) |
| Cognitive effects | Transient impairment | No impairment |
| Abuse potential | Present (Schedule III) | Not applicable |
| Systemic drug exposure | Yes | None |
The side effect profiles differ dramatically, reflecting the fundamental difference between pharmacological and electromagnetic interventions.
Ketamine's side effects -- dissociation, nausea, blood pressure elevation, and transient cognitive impairment -- are acute and self-limiting but require clinical monitoring and restrict driving for 24 hours. Abuse potential is a consideration not present with TMS.
TMS side effects are primarily localized: scalp discomfort and headache, typically mild, with no sedation, cognitive impairment, or systemic exposure. Patients can drive and resume normal activities immediately. The primary safety concern is seizure risk (<0.1%), minimized by adherence to established safety parameters and contraindication screening.
Clinical: For patients who are concerned about drug-related side effects, who have substance use histories that make controlled substance prescribing complicated, or who experience intolerable dissociative effects with ketamine, TMS offers a compelling non-pharmacological alternative with an excellent safety profile. Conversely, patients who cannot commit to 6-9 weeks of daily treatment visits, or who need rapid relief, are better candidates for ketamine.
FDA Status
| Regulatory Aspect | Ketamine Therapy | TMS Therapy |
|---|---|---|
| FDA cleared/approved for depression | Esketamine (Spravato): Yes (2019); IV racemic: No | Yes (rTMS: 2008; dTMS: 2013) |
| Specific indication | TRD; MDD with suicidal ideation | MDD (after ≥1 failed antidepressant) |
| REMS required | Yes (esketamine) | No |
| Prescription required | Yes (Schedule III) | Yes (physician order) |
TMS received 510(k) clearance in 2008 for MDD; esketamine received FDA approval in 2019 for TRD. IV racemic ketamine remains off-label. TMS does not require a REMS program, simplifying administration.
Cost and Insurance Coverage
| Cost Factor | Ketamine Therapy | TMS Therapy |
|---|---|---|
| Per-session cost | $400-1,000 (IV); $800-1,200 (esketamine) | $200-400 |
| Acute course cost | $2,400-14,400 | $6,000-15,000 |
| Annual cost (with maintenance) | $5,000-45,000 | $8,000-20,000 (if retreatment needed) |
| Insurance coverage | Limited (IV); growing (esketamine) | Increasingly covered |
TMS has a lower per-session cost but requires more sessions (30-36 vs. 6-8), resulting in comparable total acute course costs. Insurance coverage for TMS has improved substantially. TMS durability of 6-12 months may yield lower annualized costs than ongoing ketamine maintenance.
Convenience and Practical Considerations
Ketamine requires fewer sessions but causes post-treatment impairment (no driving for 24 hours). TMS requires 30-36 daily sessions but causes no impairment -- patients can drive and work immediately. The combination of ketamine and TMS is an emerging research area, with preliminary evidence suggesting that ketamine's neuroplasticity effects may prime circuits for enhanced TMS response.
References
- Carpenter LL, Janicak PG, Aaronson ST, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 29(7), 587-596. PubMed
- Cole EJ, Stimpson KH, Bentzley BS, et al. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. American Journal of Psychiatry, 177(8), 716-726. PubMed
- Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016). Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238-249. PubMed
- Dunner DL, Aaronson ST, Sackeim HA, et al. (2014). A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry, 75(12), 1394-1401. PubMed
- George MS, Lisanby SH, Avery D, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Archives of General Psychiatry, 67(5), 507-516. PubMed
- Kishimoto T, Chawla JM, Hagi K, et al. (2016). Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis. Psychological Medicine, 46(7), 1459-1472. PubMed
- O'Reardon JP, Solvason HB, Janicak PG, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biological Psychiatry, 62(11), 1208-1216. PubMed
- Wilkinson ST, Ballard ED, Bloch MH, et al. (2018). The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal of Psychiatry, 175(2), 150-158. PubMed
- National Institute of Mental Health (NIMH). Brain Stimulation Therapies. NIMH
Verdict
Ketamine and TMS address treatment-resistant depression through fundamentally different mechanisms -- pharmacological glutamate modulation versus electromagnetic neural stimulation. Ketamine offers dramatically faster onset (hours vs. weeks) and is better suited for acute crises, while TMS provides a non-pharmacological alternative with minimal systemic side effects and strong durability data. The choice depends on clinical urgency, patient preference, and access.
Share